Nov 5
PBYI · Puma Biotechnology, Inc.
$8.25
-1.52 (-15.56%)
At close · Nov 6
Return incl. dividend (before tax)
Market Cap
$404.44M
Shares
51.62M
Volume · Nov 6
1.28M
Avg daily vol (3M)
353.77K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.25
Open$8.27
Day$7.59–8.65
52W close$4.73–11.26
Avg vol 30d399K
Short int4.5M · 8.8% of shares · 12.9d
Short vol63%
Last earningsNov 5, 2026
DataJan 2020–Nov 2026
Filing10-Q · Aug 6
Up next
Dec 21, 2026
Est · unconfirmed
· in 6 wks
Latest documents
2026
Nov 5
Sep 14
Investor event
Sept. 14, 2026 - H.C. Wainwright 28th Annual Global Investment Conference
AI summary on its way
Aug 6
Aug 6
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$231.24M
Trailing 12 months
Net income (TTM)
$26.72M
Trailing 12 months
Revenue growth YoY
+7.8%
Year over year
Operating margin
13.2%
Trailing 12 months
P / E (TTM)
18.8
Trailing earnings · reciprocal yield 5.3%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$93.90M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.9%
Year over year · more shares
Price change (1Y)
+97.4%
Trailing year
Short interest
8.8%
Latest settlement · 12.9 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Puma raised full-year 2026 NERLYNX net product revenue guidance to $205–$209M (from $202–$206M) and net income guidance to $17–$20M (from $16–$19M), but cut royalty guidance to $19–$22M from $20–$23M. Q2 product revenue rose to $53.6M from $49.2M a year ago, though new prescriptions fell 6% sequentially and the company is now debt-free after a final $11.1M loan payment.
Bullish
- + Raised full-year 2026 NERLYNX net product revenue guidance to $205–$209M from prior $202–$206M.
- + Raised full-year 2026 net income guidance to $17–$20M from prior $16–$19M.
- + Q2 2026 NERLYNX net product revenue rose to $53.6M from $49.2M in Q2 2025, with ex-factory bottles up 26% sequentially and 12% year-over-year.
- + Puma is now debt-free after paying off its 2021 Note Purchase Agreement, with $93.9M in cash and securities at quarter-end.
- + Alisertib ALISCA-Breast1 trial amended to focus on 40mg and 50mg dose groups, with updated interim data expected in Q4 2026.
Bearish
- − Lowered full-year 2026 royalty guidance to $19–$22M from prior $20–$23M, with potential China generic threshold triggering further rate reduction in late 2026 or 2027.
- − Q2 commercial new patient starts declined approximately 6% sequentially.
- − Q2 gross-to-net adjustment widened to 27.9% from 27% in Q1 2026, driven by higher Medicaid share.
- − R&D expenses rose to $18.9M in Q2 from $15.5M a year ago, with full-year R&D expected to grow 34%–37% year-over-year.
- − Tax asset valuation allowance remains under review and could result in a future adjustment to net income.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 28.2 · fear
Equity put/call 0.89
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
−16%
below
RSI (14)
30
neutral
MACD trend
Negative
52-week position
54%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
+21%
trailing
YTD return
+39%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
58 of 161 funds reported for Sep 30 · net +120.1K sh shares · +7 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.80% of shares out · ▲ +6.5% MoM · 12.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
EPS growth
−2%
Y/Y
Free cash flow
$41.7M
Valuation
P/E 15.1
rich
Balance sheet
$7.1M
net cash
Quant / Vol
risk profile
Volatility
61%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 6, 2026
fiscal year 2026
Net Nerlinx product revenue
Maintained
$205M – $209M
Jul 23, 2026
$205M – $209M
changed to
Aug 6, 2026
$205M – $209M
Royalties from our partners around the world
$19M – $22M
SG&A expenses increase year-over-year
1% – 2%
R&D expenses increase year-over-year
34% – 37%
full year 2026
Gross to net adjustment
Maintained
26.5% – 27.5%
Jul 23, 2026
26.5% – 27.5%
changed to
Aug 6, 2026
26.5% – 27.5%
Net income
Maintained
$17M – $20M
Jul 23, 2026
$17M – $20M
changed to
Aug 6, 2026
$17M – $20M
Previous outlook
earlier release
· from the 8-K filed Feb 26, 2026
Still-open targets the latest release did not restate under the same label.
License Revenue
· Full Year 2026
$0
Prior guidance
period ended
· from the Earnings Call filed Aug 6, 2026
Product revenue net
· Q3 2026
$54M – $56M
Royalty revenues
· Q3 2026
$2M – $3M
Gross to net adjustment
· Q3 2026
26% – 27%
Net income
· Q3 2026
$2M – $2.5M
Guided vs delivered
· last 3 settled
Total Revenue
Second Quarter 2026
guided $52M – $55M
$56.5M
Beat +5.6%
Total Revenue
Third Quarter 2025
guided $48M – $51M
$54.48M
Beat +10.1%
Total Revenue
Full Year 2025 (current)
guided $212M – $222M
$228.37M
Beat +5.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
−16%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
54%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
58 of 161 funds reported for Sep 30 · net +120.1K sh shares · +7 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.80% of shares out · ▲ +6.5% MoM · 12.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $8 · 54%
Range high $11
vs 200-day avg +3%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash provided by operating activities | $1.6M | second quarter of 2026 | — |
| Non-GAAP adjusted net income non-GAAP | $8.3M | first six months of 2026 | — |
| Non-GAAP adjusted net income per basic and diluted share non-GAAP | $0.16 | first six months of 2026 | — |
| Non-GAAP adjusted net income per basic share non-GAAP | $0.2 | second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net income per share—basic $0.16
+$0.04 Adjustment to net income (as detailed above)
= Non-GAAP adjusted basic net income per share $0.2
|
|||
| Non-GAAP adjusted net income per diluted share non-GAAP | $0.19 | second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net income per share—diluted $0.16
+$0.03 Adjustment to net income (as detailed above)
= Non-GAAP adjusted diluted net income per share $0.19
|
|||
| Stock-based compensation as a percentage of operating expenses | 5.4% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PBYI
this stock
Puma Biotechnology, Inc.
|
$404.44M | +38.7% | -0.9% | 15.1 | 8.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$138.71B | +20.7% | +46.2% | 35.2 | 1.7% |
|
MRNA
Moderna, Inc.
|
$96.40B | +762.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$93.82B | +17.2% | +20.8% | 20.1 | 2.1% |
|
CSLLY
Csl Ltd
|
$67.11B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PBYI | -21.0% | -19.8% | +21.2% | -21.0% | +38.7% |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | -18.3% | -14.3% | +21.6% | -18.3% | +30.8% |
Key facts
CIK
1401667
CUSIP
74587V107
13F (30d)
60 filings
48 filers
Visit website
Investor relations